ProQR in licence deal with Ionis Pharmaceuticals
Dutch ProQR NV has licensed global commercialisation rights to IONIS-RHO-2.5Rx (QR-1123) from Ionis Pharmaceuticals, to treat autosomal dominant retinitis pigmentosa (adRP)
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
Newron bags 40m EIB loan
/in News/by Thomas GabrielczykThe EIB has agreed to support Italian CNS drug developer Newron Pharmaceuticals with up to 40m to support the development of the company’s late-stage pipeline.
TES Pharma presents new treatment approach towards AKI and NALFD
/in News/by Thomas GabrielczykTES Pharma has presented a novel treatment approach for acute kidney injury and non-alcoholic fatty liver disease in Nature.
MEPs vote for ban of single-use plastics
/in News/by Thomas GabrielczykThe European Parliament has approved measures that could lead to a ban of the top 10 single use plastic products that contribute to marine littering by 2021.
AstraZeneca and Innate Pharma in US$5bn oncology deal
/in News/by Thomas GabrielczykAstraZeneca plc has extended its immunoncology pipeline by an extension of its partnership with French Innate Pharma SA.
Takeda strikes US$640m deal with Enterome
/in News/by Thomas GabrielczykFrench Enterome SA has added a second licence agreement with Takeda to its deal portfolio, projecting possible payments of US$640m.
EMA recommends four biologicals for market
/in News/by Thomas GabrielczykThe European Medicines Agency delays the EU approval of Nivolumab/Ipilimumab in NSCLC and greenlights four biotherapeutics to be marketed in the EU.
Companies at EFIB set to drive the bioeconomy
/in News/by Thomas GabrielczykIndustrial biotech innovations, presented in at the 11th EFIB in Toulouse, could become the key enabler set to save our planet if supported appropriately.
Targovax reports promising disease-free survival (DFS) data
/in News/by Thomas GabrielczykTargovax ASA has reported promising disease-free survival (DFS) data from Tg01 in resected pancreatic cancer.
EU set to speed up switch to bioeconomy by new action plan
/in News/by Thomas GabrielczykSix years after the European Commission created the world’s first bioeconomy strategy and action plan, it presented a new action plan aimed at moving faster towards a climate-neutral, sustainable, biobased […]